This is a StreetInsider.com Premium Only Page

Provention Bio Inc. (PRVB) – Press Releases

Mar 13, 2023 07:00 AM Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call

Mar 3, 2023 04:05 PM Provention Bio Announces the Grant of Inducement Awards

Feb 23, 2023 08:30 AM Provention Bio to Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023

Feb 13, 2023 07:30 AM Provention Bio Announces Completion of $35 Million Equity Investment from Sanofi US

Feb 8, 2023 07:30 AM Provention Bio to Present at the SVB Securities Global Biopharma Conference

Feb 3, 2023 04:01 PM Provention Bio Announces the Grant of Inducement Awards

Feb 2, 2023 04:01 PM Provention Bio Announces Closing of Second Tranche with Hercules Capital to Support U.S. Commercial Launch of TZIELD®

Jan 24, 2023 08:56 AM AGC Biologics Supports Commercial Production of Provention Bio’s New Type 1 Diabetes (T1D) Therapy, TZIELD™

Jan 6, 2023 04:01 PM Provention Bio Announces the Grant of Inducement Awards

Jan 5, 2023 04:01 PM Provention Bio Announces Appointment of Rita Jain, M.D., to Board of Directors

Dec 2, 2022 04:01 PM Provention Bio Announces the Grant of Inducement Awards

Nov 17, 2022 05:45 PM TZIELD™ (teplizumab-mzwv) approved by FDA as the first and only treatment indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with St

Nov 4, 2022 04:05 PM Provention Bio Announces the Grant of Inducement Awards

Nov 3, 2022 07:00 AM Provention Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

Oct 13, 2022 07:30 AM Provention Bio to Report Third Quarter 2022 Financial Results on November 3, 2022

Oct 7, 2022 04:01 PM Provention Bio Announces the Grant of Inducement Awards

Oct 6, 2022 07:00 AM Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals

Sep 19, 2022 07:30 AM Provention Bio Announces Senior Leadership Addition

Sep 6, 2022 04:01 PM Provention Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Sep 2, 2022 04:01 PM Provention Bio Announces the Grant of Inducement Awards

Aug 31, 2022 06:12 PM Provention Bio Announces $125 Million Term Loan Facility with Hercules Capital

Aug 4, 2022 07:00 AM Provention Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

Aug 2, 2022 04:05 PM Provention Bio Announces the Grant of Inducement Awards

Jul 28, 2022 07:30 AM Provention Bio to Report Second Quarter 2022 Financial Results on August 4, 2022

Jul 7, 2022 07:28 PM Provention Bio Announces $60 Million Private Placement

Jul 5, 2022 04:01 PM Provention Bio Announces the Grant of Inducement Awards

Jun 30, 2022 04:01 PM Provention Bio Announces Extension of FDA User Fee Goal Date for Teplizumab to November 17, 2022

Jun 3, 2022 07:35 AM Provention Bio Announces the Grant of Inducement Awards

Jun 3, 2022 07:30 AM Provention Bio to Present at the Jefferies Global Healthcare Conference

Jun 3, 2022 07:00 AM Provention Bio Announces Update to Board of Directors

May 12, 2022 07:30 AM Provention Bio to Host a May 19, 2022 Virtual Investor Event Focused on the Potential Commercial Launch of Teplizumab Later This Year

May 5, 2022 07:00 AM Provention Bio Reports First Quarter 2022 Financial Results and Provides Business Update

May 3, 2022 07:30 AM Provention Bio Announces the Grant of Inducement Awards

Apr 28, 2022 07:30 AM Provention Bio to Report First Quarter 2022 Financial Results on May 5, 2022

Apr 4, 2022 04:05 PM Provention Bio Announces the Grant of Inducement Awards

Mar 28, 2022 07:30 AM Provention Bio Announces Positive Final Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101

Mar 21, 2022 07:00 AM Provention Bio Announces FDA Acceptance of the Biologics License Application (BLA) Resubmission for Teplizumab for the Delay of Clinical Type 1 Diabetes in At-Risk Individuals

Mar 4, 2022 04:05 PM Provention Bio Announces the Grant of Inducement Awards

Mar 3, 2022 07:30 AM Provention Bio to Present at Two Upcoming Virtual Investor Conferences

Feb 24, 2022 07:00 AM Provention Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Feb 22, 2022 07:30 AM Provention Bio Announces Biologics License Application (BLA) Resubmission for Teplizumab to Address Complete Response Letter (CRL)

Feb 17, 2022 04:05 PM Provention Bio to Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022

Feb 10, 2022 07:30 AM Provention Bio to Present at the Virtual SVB Leerink 11th Annual Global Healthcare Conference

Feb 4, 2022 04:05 PM Provention Bio Announces the Grant of Inducement Award

Jan 27, 2022 04:05 PM Provention Bio Resubmitting Biologics License Application for Delay of Clinical Type 1 Diabetes in At-Risk Individuals Following Type B Meeting with the FDA

Jan 20, 2022 04:05 PM Provention Bio Announces Initiation of the Phase 2a PREVAIL-2 Study of PRV-3279 (CD32B × CD79 Bispecific DART® Molecule) in Systemic Lupus Erythematosus (SLE)

Jan 7, 2022 07:30 AM Provention Bio Announces the Grant of Inducement Awards

Jan 6, 2022 07:30 AM Provention Bio to Present at the Virtual H.C. Wainwright BioConnect Conference

Dec 20, 2021 07:34 AM Provention Bio Announces Leadership Team Expansion

Dec 2, 2021 07:30 AM Provention Bio Announces the Grant of Inducement Awards